Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components

Carregando...
Imagem de Miniatura
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2013
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CLINICS, v.68, n.6, p.834-839, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVE: To compare the efficacy and tolerability of a fixed combination of 0.3% gatifloxacin and 1% prednisolone (Zypred (R)) versus the individual components used separately (Zypred (R) and Predfort (R)) for infection prophylaxis and inflammation control after cataract surgery with intraocular lens implantation. METHODS: A prospective, randomized, double-blind, parallel-group study of 108 patients who underwent phacoemulsification and intraocular lens implantation was conducted. After random assignment, 47 eyes received the fixed combination of topical 0.3% gatifloxacin/1% prednisolone drops, and 61 eyes received the same doses of the individual components as separate solutions four times a day for 15 days. Baseline and postoperative assessments were made on postoperative days 1, 7, 15, and 20. RESULTS: All objective (best corrected visual acuity, sign of active ocular inflammation, central and incisional corneal edema, the number of cells per high-power field in the anterior chamber, and intraocular pressure) and subjective (eye pain, photophobia, burning sensation, itching, and foreign body sensation) criteria of efficacy were similar in both groups, with no significant differences. Group I included 47 eyes that received the fixed combination of gatifloxacin/prednisolone acetate eye drops and a placebo eye drop solution. Group II included 61 eyes that were treated with 0.3% gatifloxacin and 1% prednisolone acetate eye drops separately. The intraocular pressure was slightly higher in Group II (p<0.05). CONCLUSION: Treatment with the fixed-dose combination of gatifloxacin/prednisolone eye drops was as effective as the non-fixed combination in preventing infection and controlling inflammation after phacoemulsification and intraocular lens implantation.
Palavras-chave
Cataract Extraction, Gatifloxacin, Prednisolone, Phacoemulsification
Referências
  1. Awan MA, 2009, BRIT J OPHTHALMOL, V93, P708, DOI 10.1136/bjo.2008.154906
  2. Ayaki M, 2010, BIOCONTROL SCI, V15, P97
  3. Ayaki M, 2008, CLIN EXP OPHTHALMOL, V36, P553, DOI 10.1111/j.1442-9071.2008.01803.x
  4. Beltrani VS, 2005, IMMUNOL ALLERGY CLIN, V25, P557, DOI 10.1016/j.iac.2005.05.006
  5. Campos Mauro, 2011, Clin Ophthalmol, V5, P209, DOI 10.2147/OPTH.S17059
  6. Chan E, 2010, CLIN EXP OPTOM, V93, P379, DOI 10.1111/j.1444-0938.2010.00516.x
  7. Costello P, 2006, RETINA-J RET VIT DIS, V26, P191, DOI 10.1097/00006982-200602000-00012
  8. Eady EA, 1994, REV MED MICROBIOL, V5, P163
  9. Epstein SP, 2009, J OCUL PHARMACOL TH, V25, P113, DOI 10.1089/jop.2008.0098
  10. Ilyas Haroon, 2004, Eye Contact Lens, V30, P10, DOI 10.1097/01.ICL.0000092071.82938.46
  11. Jakab E, 1996, YALE J BIOL MED, V69, P477
  12. Juarez-Verdayes MA, 2012, MICROB PATHOGENESIS, V52, P318, DOI 10.1016/j.micpath.2012.03.001
  13. Kim DH, 2005, OPHTHALMOLOGY, V112, P1992, DOI 10.1016/j.ophtha.2005.06.017
  14. Kim SJ, 2011, ARCH OPHTHALMOL-CHIC, V129, P1180, DOI 10.1001/archophthalmol.2011.213
  15. Laurell CG, 2002, BRIT J OPHTHALMOL, V86, P1380, DOI 10.1136/bjo.86.12.1380
  16. LEYDHECKER W, 1958, Klin Monbl Augenheilkd Augenarztl Fortbild, V133, P662
  17. Liu XA, 2010, CHINESE MED J-PEKING, V123, P2105, DOI 10.3760/cma.j.issn.0366-6999.2010.15.027
  18. McCulley JP, 2006, OPHTHALMOLOGY, V113, P955, DOI 10.1016/j.ophtha.2006.01.061
  19. Miller JJ, 2005, AM J OPHTHALMOL, V139, P983, DOI 10.1016/j.ajo.2005.01.025
  20. Mollan SP, 2007, J CATARACT REFR SURG, V33, P265, DOI 10.1016/j.jcrs.2006.10.022
  21. Notivol R, 2004, CLIN DRUG INVEST, V24, P523, DOI 10.2165/00044011-200424090-00003
  22. O'Brien TP, 2007, J CATARACT REFR SURG, V33, P1790, DOI 10.1016/j.jcrs.2007.06.026
  23. Ong-Tone L, 2007, J CATARACT REFR SURG, V33, P59, DOI 10.1016/j.jcrs.2006.09.015
  24. Price MO, 2005, J CATARACT REFR SURG, V31, P2137, DOI 10.1016/j.jcrs.2005.04.032
  25. Reddy Rahul, 2011, Clin Ophthalmol, V5, P751, DOI 10.2147/OPTH.S7633
  26. RENFRO L, 1992, DERMATOL CLIN, V10, P505
  27. Schlech BA, 2005, SURV OPHTHALMOL, V50, pS64, DOI 10.1016/j.survophthal.2005.05.005
  28. Smith MA, 1996, J CLIN MICROBIOL, V34, P1024
  29. Solomon R, 2005, OPHTHALMOLOGY, V112, P466, DOI 10.1016/j.ophtha.2004.09.029
  30. van Endt J J, 1997, Eur J Ophthalmol, V7, P144
  31. ZAMBRANO W, 1989, OPHTHALMOLOGY, V96, P1100